Alto Neuroscience

Our CEO, Dr. @AmitEtkin, joined The BioHub Podcast to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health. Listen on Spotify, Apple Podcasts, or LinkedIn. linkedin.com/posts/max-bren… #Neuroscience #MentalHealth #HealthcareInnovation

Today, @AltoNeuro reported full-year 2025 financial results and recent business highlights. Learn more about our pipeline and upcoming milestones here: investors.altoneuroscience.com/news/news-deta…

@AltoNeuro is excited to present at the Stifel 2026 Virtual CNS Forum - hear from our leadership team on March 17th at 12pm ET about our mission to redefine psychiatry with precision medicine. Learn more here: investors.altoneuroscience.com/news/news-deta… #PrecisionPsychiatry #StifelCNS

Alto Neuroscience is heading to TD Cowen and Jefferies Biotech on the Beach this month! Hear from our leadership team on our mission to redefine psychiatry with personalized precision medicines. Learn more: lnkd.in/gXcqBEpN #AltoNeuroscience #PrecisionPsychiatry

Our CEO, Dr. @AmitEtkin, joined @thehctheory to discuss precision psychiatry and moving beyond trial-and-error treatment in mental health. Listen on #Spotify, #ApplePodcasts, or #thehctheory website. thehealthcaretheory.org/a-new-blueprin… #Neuroscience #MentalHealth #HealthcareInnovation

New publication in the American Journal of Psychiatry: @AltoNeuro highlights neuroplasticity as a core, druggable driver of psychiatric disease, reinforcing the scientific foundation of our precision psychiatry platform. businesswire.com/news/home/2026… #Neuroscience #MentalHealth

#ICYMI: New data from @AltoNeuro at ACNP 2026 underscore the strength of our precision platform and advancing clinical pipeline. Details: investors.altoneuroscience.com/news/news-deta…

At #JPMWeek, our CEO @AmitEtkin sat down with @JonahComstock, Editor-in-Chief of @pharmaphorum, to discuss @AltoNeuro's biology-driven approach and what’s ahead in schizophrenia, depression, and bipolar disorder. 🎥 Full interview: pharmaphorum.com/rd/year-precis… #Neuroscience

@AltoNeuro announced a new U.S. method-of-treatment patent for ALTO-207 in depression, strengthening protection for this differentiated program in treatment-resistant patients. investors.altoneuroscience.com/news/news-deta… #PrecisionPsychiatry #Depression #Neuroscience #Biotech

Today, @AltoNeuro reported financial results for the quarter ended September 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates. Learn more here: investors.altoneuroscience.com/news/news-deta…

A proud day for Alto Neuroscience at the @NYSE. We rang the Opening Bell today to celebrate our ongoing commitment to transforming the treatment of mental health disorders through precision psychiatry.

Excited to join the conversation at upcoming investor conferences! Stifel 2025 Healthcare Conf. – Nov 12, 10:00 AM ET, NYC Jefferies London Healthcare Conf. – Nov 17, 3:30 PM GMT Webcasts: altoneuroscience.com/investors Read more here: investors.altoneuroscience.com/news/news-deta… #Biotech #Neuroscience

@AltoNeuro is pleased to announce the close of a $50 million private placement financing. Read more here: bit.ly/4716dVg #TRD #financing #biotech #neuroscience #precisionpsychiatry

@AltoNeuro announced today that it will accelerate the development of ALTO-207 for people with treatment-resistant depression (TRD), following a successful outcome from a recent meeting with @FDA. investors.altoneuroscience.com/news/news-deta… #TRD #biotech #neuroscience

At #ECNP2025, Dr. Mike Browning presented key results previously reported in The Lancet from the PAX-D study. These results guided Alto’s acquisition of ALTO-207, designed to induce rapid antidepressant effects while mitigating dose-limiting adverse events of pramipexole.

This #WorldMentalHealthDay, the focus is “Access to Services: Mental Health in Catastrophes and Emergencies.” At @AltoNeuro, we’re advancing neuroscience to make effective, personalized mental health care available to all. #MentalHealthAwareness #Neuroscience #AccessToCare

Encouraging news from @AltoNeuro: the @US_FDA has granted Fast Track designation to ALTO-101 for treating cognitive impairment in schizophrenia (CIAS). No approved therapies exist today—together, we’re working to change that. Learn more here: bit.ly/3IMDAll #FastTrack

Grateful to @PrecMedOnline for highlighting @AltoNeuro's mission: bringing precision psychiatry to patients through EEG biomarkers. Our goal is simple — the right treatment, for the right patient, at the right time. Learn more here: bit.ly/46wHMii #PrecisionMedicine

We're in the spotlight! Our CEO, Amit Etkin, MD, PhD, shares how we’re advancing drug development for cognitive impairment in schizophrenia, plus new EEG biomarker insights. ▶️ Video: bit.ly/3IAhi67 📰Article: bit.ly/3KdNTiJ #Schizophrenia #Neuroscience

This week, our CEO, @AmitEtkin, will discuss Alto’s recent corporate updates during a fireside chat at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. Tune in here: wsw.com/webcast/cowen1…